Dual Angiotensin Receptor and Neprilysin Inhibition in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
CONCLUSIONS: LCZ696 significantly improved morbidity and mortality in patients with chronic HFrEF but will require careful application to "real-world" populations of HFrEF.
PMID: 26175499 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Lillyblad MP Tags: Ann Pharmacother Source Type: research
More News: Cardiology | Diovan | Drugs & Pharmacology | Enalapril | Heart | Heart Failure | Neurology | Study